Decoding impact of human papillomavirus in gynecological oncology: a narrative review

Article information

Obstet Gynecol Sci. 2025;68(1):30-42
Publication date (electronic) : 2025 January 9
doi : https://doi.org/10.5468/ogs.24226
1Virology Laboratory, Programme for Emerging Infections, Infectious Diseases Division, icddr,b, Dhaka, Bangladesh
2Hospital, Nutrition and Clinical Services Division, icddr,b, Dhaka, Bangladesh
Corresponding author. Md. Safiullah Sarker, PhD Virology Laboratory, Programme for Emerging Infections, Infectious Diseases Division, icddr,b, 68 Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka 1212, Bangladesh E-mail: ssarker@icddrb.org
Received 2024 August 9; Revised 2024 October 21; Accepted 2024 December 12.

Abstract

Human papillomavirus (HPV) is a key factor in gynecological oncology. This narrative review investigates the complex connection between HPV and various gynecological cancers. For a comprehensive exploration, we examined the association between persistent HPV infection and cervical cancer and its global prevalence. Beyond the cervix, we navigated the linkages between HPV and other gynecological malignancies, shedding light on vulvar, vaginal, anal, and oropharyngeal cancers. The narrative extends to discuss the critical role of HPV vaccination in preventing these cancers and exploring challenges, controversies, and future perspectives in the field. As we have described the impact of HPV, this review underscores the significance of ongoing research and public health endeavors in shaping the trajectory of gynecological oncology.

Introduction

1. Significance of gynecological oncology and the impact of human papillomavirus (HPV) on women’s health

Gynecological oncology is the field of medicine that focuses on the diagnosis and treatment of cancers affecting the female reproductive system and includes cervical, vulvar, vaginal, and ovarian cancers.

It plays a significant role in women’s health by providing specialized care for these types of cancers. HPV infection is a major contributor to the development of gynecological cancers. HPV is a sexually transmitted infection that can cause cervical, vulvar, vaginal, and anal cancers, leading to the development of anogenital warts. Studies have identified HPV infection as an essential factor in the development of cervical cancer and have linked it to the etiology of other gynecological cancers [1].

The impact of HPV infection on women’s health is extensive. In 2002, HPV infections accounted for a significant number of cervical and non-cervical HPV-related cancers worldwide, including cervical, anal, oropharyngeal, penile, vaginal, and vulvar cancers [1]. The incidence of cervical cancer in the United States has decreased largely because of the effectiveness of Pap smear screening. However, the incidence of other gynecological cancers, including anal, oropharyngeal, and vulvar cancers has increased [1].

The introduction of highly effective vaccines targeting HPV types 16 and 18 has significant potential for preventing the majority of cervical and non-cervical HPV-related cancers [1]. Vaccination against HPV 16/18 could potentially prevent approximately 8,500 cases of gynecological cancer and precancer annually in Denmark, Iceland, Norway, and Sweden [2]. However, barriers to HPV vaccination and cervical cancer screening exist, including accessibility, affordability, sociocultural factors, and healthcare system limitations [3].

2. High prevalence of HPV infections and their association with gynecological cancers

The high prevalence of HPV infections and their association with gynecological cancers, particularly cervical cancer, have been well-established in literature. HPV is the primary cause of cervical cancer, and nearly 100% of cases are attributed to HPV infection [4]. HPV is primarily transmitted through sexual means and is closely associated with the development and progression of cervical cancer [4]. The transition from a persistent HPV infection to invasive cervical cancer spans a minimum of 10 years. This progression is characterized by early dysplastic epithelial changes [5].

To address this issue, HPV vaccination has been identified as an important measure to prevent or treat HPV infection and reduce the incidence of cervical cancer [5]. Vaccination before sexual debut has been shown to effectively prevent HPV infections, precancers, and cancers [6]. However, the underuse of HPV vaccination remains a concern in many countries, including the United States [7].

In addition to vaccinations, screening programs have successfully decreased the incidence of cervical cancer by detecting precancerous changes. HPV testing has been recognized as the most effective method for detecting precancers and cancers in individuals between the ages of 25 and 65 [8]. Ensuring sufficient screening, especially around menopause, is essential to prevent cervical cancer in older women [8].

Background on HPV

1. Comprehensive overview of HPV, its types, and modes of transmission

HPV is the most widespread sexually transmitted viral infection globally [9]. Certain strains of HPV are known to cause cancer, underscoring the importance of infection prevention strategies, including vaccination [9].

Most HPV strains belong to the genus Alphapapillomavirus which can be further subdivided into species and strains [10]. Approximately 200 HPV strains have been identified, with 12 strains classified as having high oncogenic risk [10]. These high-risk strains of HPV include types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 [11].

HPV is primarily transmitted through sexual contact, including vaginal, anal, and oral sex [12]. It can also be transmitted through non-sexual routes, such as mother-to-child transmission during childbirth or through skin-to-skin contact [13].

Notably, coinfection with multiple HPV types is possible, and the occurrence of coinfection does not necessarily predict the acquisition or persistence of other HPV types [14]. The host immune response to HPV is type-specific, and the prevention or elimination of one HPV type, such as HPV-16, is unlikely to increase the risk of infection with other types [14].

2. Epidemiology of HPV, emphasizing its global prevalence and the populations most at risk

The global prevalence of HPV varies by region. According to several studies [15], the highest HPV rates have been reported in Africa (24%), Eastern Europe (21.4%), and Latin America (16.1%). These regions have a higher burden of HPV infections than other parts of the world. The most common HPV types worldwide are HPV 16, 18, 52, 31, and 58 [15].

Certain populations are considered to be at a higher risk of HPV infection. The LGBTTIQA population (Lesbian, Gay, Bisexual, Transgender, Transvestite, Intersex, Queer, and Asexual) is one such group that may face greater risks of infection due to social stigmatization and barriers to healthcare services [16]. Moreover, individuals with a weakened immune system, such as those living with human immunodeficiency virus (HIV), are at higher risk of HPV infection [17].

To address the global burden of HPV, it is crucial to improve and implement HPV vaccination programs, especially in low- and middle-income countries where the prevalence is high. With increasing vaccination rates, the incidence of HPV-related diseases, including cervical cancer, could be reduced [18].

HPV and cervical cancer

1. Link between persistent HPV infection and cervical cancer

Persistent HPV infection is crucial for cervical cancer development. Although HPV infection is widespread, only persistent high-risk HPV (HR-HPV) infection leads to cervical cancer, which takes many years and involves dysplastic epithelial changes. Persistent HR-HPV infection is essential for the development of cervical cancer, but alone is not sufficient to cause it. Other factors are also required for cancer [19,20]. It typically takes at least 10 years for persistent HPV infection to progress to invasive cervical cancer [21].

Therapeutic vaccines are being developed to eliminate established HPV infections, with research emphasizing the potential of prophylactic and therapeutic vaccines [22]. Epigenetic changes such as hypermethylation and tumor suppressor gene downregulation increase high-grade intraepithelial neoplasia (IN) and cancer [23].

Genetic studies have shown that polymorphisms, such as matrix metalloproteinase-2 C1306T polymorphism, significantly increase cervical cancer risk, with the CC genotype presenting a 4.33-fold higher risk [24]. Despite the limited randomized evidence, observational studies have highlighted an association between HPV infection, cervical intraepithelial neoplasia (CIN), and cervical cancer [25]. New prevention strategies, including cost-effective cervical cancer screening, are essential, particularly for women not protected by HPV vaccination [26].

2. HR-HPV types and their oncogenic potential

HPV-16 and HPV-18 are HR types associated with cervical cancer, whereas HPV-6 is a low-risk type. Barbosa et al. [27] found significant differences in the early protein 7 (E7) protein’s expression between high- and low-risk HPVs. Kovelman et al. [28] showed that E2 proteins from HR HPVs have greater transcriptional activation capabilities than those from low-risk types.

Kraus et al. [29] validated the effectiveness of the PreTect HPV-proofer assay for detecting HR HPV types in cervical carcinomas. Kusanagi et al. [30] found that gastric-type adenocarcinomas are often HPV-independent, suggesting limitations in HPV DNA testing and vaccination.

HR HPVs, including types 16, 18, 45, 52, and 58, are linked to a higher risk of epithelial malignancies, particularly cervical squamous cell carcinoma [31,32]. These variations highlight the need for localized studies and tailored prevention strategies to combat HPV-associated cancers.

1) Role of HPV testing in cervical cancer screening and prevention

HPV testing is pivotal in cervical cancer screening, surpassing Pap tests for the detection of cervical precancer and cancer [33]. HR HPV types, including non-16/18 variants, play a crucial role in cervical cancer development [34]. The cervicovaginal microbiome influences precancerous lesions and potentially affects the outcome of cervical dysplasia [35].

Condic et al. [36] evaluated Germany’s new cervical cancer screening program, revealing low detection rates for high-grade CIN III, and advocating cost-effective triage tests. Rad et al. [37] underscored the need for effective triage methods by comparing the HPV DNA and messenger Ribonucleic Acid tests. Musa et al. [35] suggested that point-of-care HR-HPV testing could enhance early detection by considering vaginal microbiome types. Sudhakaran et al. [38] found that HPV testing during pregnancy is feasible and potentially improves screening in resource-limited settings.

Lawson et al. [39] documented the widespread use of visual inspection with acetic acid and HPV DNA testing in Nigerian facilities, supporting the integration of HPV testing into screening programs. HPV testing has increasingly replaced Pap smears owing to its superior ability to detect high-grade lesions [40]. Martinelli et al. [41] highlighted self-collected samples for detecting high-grade lesions and improving accessibility. Nakowong et al. [42] advanced HPV detection with an HPV-16 electrochemical biosensor.

The advantages of HPV testing include objectivity, automation, and rapid results, which lead to cost savings (cited earlier). With the expansion of HPV vaccination, the role of HPV testing in cervical cancer prevention has become critical, prioritizing secondary triage for HPV-positive women [43].

HPV and other gynecological cancers

1. Association between HPV and other gynecological cancers such as vulvar, vaginal, anal, and oropharyngeal cancers

The association between HPV and other gynecological cancers, including vulvar, vaginal, anal, and oropharyngeal cancers, has been extensively studied. Acevedo-Fontanez et al. [44] found that women with HPV-related gynecological cancers in Puerto Rico had a significantly elevated risk of developing anal cancer compared to those with non-HPV-related cancers. This study highlights the link between HPV and secondary anal cancer in women.

Yamazaki [45] reported cases of secondary cervical cancer in patients with oropharyngeal cancer treated with chemoradiotherapy, suggesting a potential association between HPV-related gynecological cancer and oropharyngeal cancer. Riethmuller et al. [46] assessed the impact of a nonavalent HPV vaccine on anogenital and oropharyngeal HPV-related diseases in France, highlighting the broad spectrum of HPV-associated malignancies.

HPV infection is crucial for the development of genital warts; oropharyngeal cancers; and various anogenital cancers, including cervical, vaginal, vulvar, anal, and penile cancers [46]. Zahnd et al. [47] demonstrated higher rates of these cancers in rural than in urban populations in the United States, underscoring disparities in the HPV-related cancer burden.

Research on the role of HPV in colorectal cancer among Puerto Rican Hispanics by Bernabe-Dones et al. [48] revealed a notable prevalence of HPV in colorectal tumors, particularly HPV-16 integration, highlighting a potential link with oncogenic processes in this population.

Overall, these studies emphasize the multifaceted impact of HPV on various gynecological cancers beyond cervical cancer, necessitating ongoing research to elucidate the underlying mechanisms and optimize screening and prevention strategies.

2. Prevalence and risk factors associated with HPV-related gynecological malignancies

HPV infection plays a significant role in the development of various gynecological malignancies. Smith et al. [49] high-lighted the importance of HPV vaccination before puberty for preventing HPV-related genital and oral diseases, underscoring the prevalence of HPV DNA in children. Nielsen et al. [50] identified risk factors associated with prevalent high-risk HPV infections, emphasizing the need for targeted prevention strategies based on population-based cohort data.

Pytynia et al. [51] discussed the increased incidence of HPV-related oropharyngeal squamous cell carcinoma among middle-aged white men, linking sexual behavior as a risk factor. In contrast, low-risk HPV is less frequently implicated in sinonasal inverted papillomas, although its presence may affect disease biology through mechanisms such as epidermal growth factor receptor expression and potentially malignant progression [52].

Teixeira et al. [53] investigated cervical cytological abnormalities and HR HPV prevalence among women living with HIV and identified age as a factor associated with HR-HPV infection. Sehnal et al. [54] estimated the risk of developing oral squamous cell carcinoma (OSCC) in women with anogenital HPV infections and noted a significant association between OSCC and HPV-related genital cancers, particularly vulvar malignancies.

Additionally, Nang et al. [55] assessed the prevalence and genotype distribution of HR HPV among women in Uganda and revealed a predominance of HPV types beyond 16 and 18, which are often linked to multiple infections. These studies underscore the complex epidemiology of HPV-related gynecological cancers and the importance of tailored prevention and management approaches based on regional and demographic factors.

HPV vaccination

1. An overview of available HPV vaccines, their efficacy, and recommendations for vaccination

HPV vaccines are safe and effective in preventing HPV infections that can lead to various cancers and genital warts. Martínez-Gómez et al. [56] conducted a systematic review to confirm the immunogenicity, safety, and efficacy of these drugs in high-risk populations. Despite their effectiveness, vaccination rates among key groups, such as young men who have sex with men, remain low, highlighting barriers such as knowledge gaps and stigma [57].

Educational efforts predominantly target patients and parents, rather than healthcare providers; however, provider recommendations significantly influence vaccine uptake [58]. Studies in diverse settings, such as Lebanon, underscore the importance of addressing physicians’ attitudes and clinical practices towards HPV vaccination to enhance acceptance [59].

The efficacy of the HPV vaccines, including the potential benefits of a single-dose regimen, was examined. Whitworth et al. [60] reviewed the evidence suggesting that one dose may be as effective as multiple doses, pending further robust trials. Sonawane et al. [61] explored parental perspectives in the US, revealing factors influencing vaccine initiation and completion, such as safety and effectiveness concerns.

Healthcare providers’ attitudes and communication skills significantly affected vaccine uptake. Lin et al. [62] emphasized the role of provider knowledge and clear communication in promoting HPV vaccination. Recent expansions in HPV vaccination eligibility for adults aged 27-45 highlight the importance of tailored communication about vaccine benefits and risks [63,64].

In summary, while HPV vaccines are effective tools for preventing HPV-related cancers and diseases, improving vaccination rates requires addressing barriers, such as knowledge gaps, provider attitudes, and patient concerns, through targeted educational interventions and clear communication strategies.

2. Impact of HPV vaccination on the prevention of gynecological cancers

The impact of HPV vaccination on the prevention of gynecological cancers, including cervical cancer, has been well documented in numerous studies. HPV infection is the primary cause of cervical cancer, and contributes significantly to the development of other genital cancers, including vulvar, vaginal, and anal cancers [65]. HPV vaccination is an important measure for preventing or treating HPV infections and reducing the incidence of cervical cancer [66].

Studies have shown that HPV vaccination is safe and effective in preventing HPV infection and subsequent development of cervical cancer. The recently approved 9-valent HPV vaccine provides extensive protection against several oncogenic HPV strains and may protect against over 80% of invasive cervical cancers [67]. This vaccine has been found to have excellent safety and efficacy [67].

Furthermore, post-licensure studies demonstrated the continued effectiveness of HPV vaccination against genital warts, which is the first outcome to be measured [68]. Age at the time of vaccination appears to play a pivotal role in vaccine effectiveness.

Challenges and controversies

1. Challenges in HPV-related gynecological oncology, include issues related to screening, vaccination coverage, and disparities in access to healthcare

Challenges in HPV-related gynecological oncology include issues related to screening, vaccination coverage, and disparities in healthcare access. Cervical cancer screening is an important preventive measure; however, there are barriers to its widespread implementation. In some countries, screening programs are ineffective, leading to a high prevalence of cervical cancer [69]. Additionally, there are disparities in screening participation, with underserved minority women having limited access to screening [70].

Vaccination coverage is another challenge in HPV-related gynecological oncology. Although the HPV vaccine is a powerful tool for cancer prevention, its uptake is not optimal. In some studies, only a small percentage of eligible women received the HPV vaccine [71]. There are disparities in vaccine uptake, with uninsured women being less likely to be vaccinated [71].

Disparities in access to healthcare also contribute to the challenges in HPV-related gynecological oncology. Uninsured women have lower vaccination and screening rates than insured women [71]. Sociocultural barriers and weaknesses in the healthcare system also affect HPV vaccination and cervical cancer screening coverage [72].

2. Controversies surrounding HPV testing and vaccination

Controversies surrounding HPV testing and vaccination have been a subject of discussion in the scientific community. HPV vaccines have demonstrated high efficacy in preventing persistent infections and precancerous lesions associated with HPV vaccine types. There is a debate regarding the optimal age for vaccination and the need for catch-up vaccination beyond a certain age [73]. Furthermore, the incorporation of HPV vaccination into national immunization programs poses challenges, especially in low- and middle-income countries. Improved access models and enhanced technical capacities are required to accelerate vaccine delivery [73].

Regarding HPV testing, there is an ongoing debate regarding the most effective strategies for cervical cancer screening. Some studies have suggested that strategies that incorporate HPV testing are more effective and cost-effective than those that incorporate cytology alone [74]. However, there are concerns regarding the overuse of cytology and the need for equitable coverage in screening programs [74]. The impact and cost-effectiveness of HPV vaccination and its potential effects on existing cervical cancer prevention programs are still being studied [75].

Future perspectives

1. Ongoing research and advancements in the field of HPV and gynecological oncology

Muñoz et al. [76] contributed to ongoing scholarly debates by focusing on issues such as measurement concepts, research designs, and dimensions of measurement in their study. Walboomers et al. [77] explored the application of machine learning in radiation oncology, highlighting its potential to optimize clinical processes and support decision making in precision medicine. The development of multitargeted drug molecules for treating gynecological cancers was reviewed, addressing the physical, biological, and psychosocial impacts that are crucial for therapeutic advancements [78]. Kjaer et al. [79] summarized the biological significance of HPV in cervical carcinogenesis, emphasizing its importance in oncology research. Wright et al. [80] conducted a bibliometric analysis across key oncology journals, discussing trends in research publications, and advocating for increased representation of women in oncology research. Dalal et al. [81] covered various health issues in women, including gynecological diseases, menstrual dysfunction, fertility management, urogynecological issues, and gynecological oncology, highlighting advancements in nursing science to improve patient outcomes. Abdou et al. [82] reviewed immunotherapeutic approaches for triple-negative breast cancer, focusing on immunotherapy beyond checkpoint inhibitors and explored new avenues for treatment efficacy and safety. Levin et al. [83] analyze top-cited original articles in gynecologic oncology, general obstetrics, and gynecology journals using bibliometric methods to assess trends and impactful research contributions.

Ongoing research on HPV and gynecological oncology has led to significant breakthroughs in the understanding, prevention, and treatment of HPV-related cancers, particularly cervical cancer. HPV, specifically high-risk strains like HPV 16 and 18, are now well established as a leading cause of cervical cancer [76,77]. Advances in vaccines have been pivotal with the introduction of vaccines that not only prevent HPV infection but also protect against multiple strains, offering broader protection against other gynecological cancers, such as vulvar and vaginal cancers [78,79]. Current research has also focused on enhancing screening methods, with HPV DNA testing demonstrating greater sensitivity and earlier detection of precancerous lesions than traditional Pap smears [80]. Immunotherapy, especially with immune checkpoint inhibitors, has shown promise for treating advanced and recurrent cervical cancer, potentially improving survival rates [81]. Researchers are exploring therapeutic vaccines that target HPV-infected cells to treat existing infections and prevent cancer progression [82]. Global efforts are underway to improve access to both preventive measures and treatments, particularly in low- and middle-income countries that bear a disproportionate burden of HPV-related cancers [83]. These advancements are critical in the ongoing battle against HPV-associated gynecological malignancies.

2. Potential future interventions and innovations in HPV prevention and treatment

Cervical cancer prevention is expected to undergo significant changes in the coming decades. HPV DNA typing will likely replace Pap smears, and two highly effective vaccines targeting the main HPV types (16 and 18) are currently available [84]. Women and healthcare providers are facing two major shifts in their understanding of cervical cancer. First, while most HPV infections resolve on their own, persistent infections with specific HPV genotypes are responsible for most cases of cervical cancer, including the less common adenocarcinomas. Second, close contact, including both penetrative and non-penetrative sexes, is the primary mode of HPV transmission. Khorasanizadeh et al. [85] explored the rates of cervical cancer incidence and mortality, along with the prevalence of high-risk HPV infections in Iran. Despite concerns about cost-effectiveness, the available HPV vaccine has the potential to prevent HPV infections and cervical cancer in Iran. The study detected that the prevalence of HPV DNA was 81.7% (94 out of 115), with a significant proportion of multiple HPV infections, accounting for 55.0% of the cases. Therapeutic vaccines capable of eradicating HPV infections or treating cancers caused by HPV infections have not yet been developed. Cole et. al. [86], 2023 identified a greater impact from the use of immunotherapy and the prevention of HPV infections, which are responsible for 98% of cervical cancer cases. Zhang et al. [87] reviewed advancements in immunotherapy for HPV-associated cancers and highlighted recent progress in understanding the immunopathology of HPV infections. Zoa Assoumou et al. [88] investigated the prevalence and distribution of HPV in Gabonese women with normal cytology and cervical abnormalities. HPV infection is closely associated with the onset of cervical IN. They also play significant roles in the development of invasive cervical cancer. These infections play a critical role in the development of serious conditions. Lima et al. [89] investigated how specific genetic polymorphisms-interleukin (IL)-6-174 G>C, IL-8 +396 G>T, and transforming growth factor beta 1+869 G>C, and +915 G>C-relate to susceptibility to HPV infection. Their study focused on women in Pernambuco, Brazil. This study aimed to understand the genetic factors that influence the risk of HPV infection in this population [89]. Arora et al. [90] assessed the knowledge about HPV-associated OSCC among oral health professionals working in dental faculties in Malaysia. The questionnaire collected data on participants’ demographics, awareness of the HPV-OSCC link, knowledge of the HPV vaccine, and willingness to educate patients about this connection. This was a cross-sectional study. The numerous unmet needs related to infections highlight promising opportunities for the advancement of targeted drug delivery technologies, particularly in the field of nanomedicine. Rubey and Brenner [91] reviewed various innovative approaches in preclinical development, including two therapies that have reached clinical use and explored further opportunities for technological advancements in infection treatments. HPV, a well-known causative agent of warts, has recently garnered significant attention owing to its potential association with various cancers. Mukherjee et al. [92] investigated the molecular pathogenesis, pathogen associations, and therapeutic strategies for managing HPV infections. HPV infections have been explored from various perspectives, including virology, epidemiology, etiology, immunology, clinical symptoms, and treatment. Although there is no cure for HPV infections, vaccines can prevent infections caused by the most common HPV types. However, despite their widespread availability, their use remains limited.

In recent years, significant advancements have been made in the fight against HPV infection. One area of innovation is the development of HPV vaccines. Prophylactic HPV vaccines, such as those targeting viral capsid proteins L1 and L2, have successfully prevented HPV infection by inducing neutralizing antibodies [93]. Additionally, therapeutic HPV vaccines are being developed to target nonstructural early viral antigens such as E6 and E7 to treat established HPV infections and HPV-associated malignancies [93].

Another innovative area is the use of nanotechnology to deliver anticancer drugs and vaccines against HPV. The nanodelivery of preventive and therapeutic HPV vaccines has shown promise in increasing vaccine efficacy and minimizing side effects [94].

These innovations in HPV prevention and treatment have great potential for controlling and eradicating oncogenic HPV infections and HPV-related cancers. However, challenges still exist, including the costs of HPV prevention and medical care, implementation barriers, and socio-political resistance [95]. Efforts are crucial to achieve the widespread implementation of HPV prevention strategies. These include routine introduction of HPV vaccines, expansion of screening programs, and consideration of a broader range of cancers and diseases that can be prevented by HPV vaccination [95].

Conclusion

1. Key findings and implications discussed in the review

The key findings and implications discussed in the context of fighting HPV infections are as follows.

1) Prevention through vaccination: HPV vaccination is recognized as a primary prevention tool for cervical cancer. The bivalent and quadrivalent HPV vaccines have been shown to have excellent safety and efficacy profiles. A 9-valent vaccine has also been developed, that may protect against over 80% of invasive cervical cancers. The World Health Organization strongly recommends HPV vaccination programs [96]. 2) Screening strategies: current cervical cancer screening strategies involve cytology combined with HPV testing. There has been a shift towards the use of HPV testing alone as a primary screening tool. HPV testing is the most effective method for detecting precancers and cancers in individuals aged 25 to 65. Thorough screening during menopause may be crucial for the prevention of cervical cancer in older women [97]. 3) Global efforts and coordination: a revised approach to cervical cancer prevention involves strategic combinations of HPV vaccination, expanded and simplified screening programs, and recognition of a wider range of cancers and diseases preventable by HPV vaccination. To achieve a significant reduction in HPV transmission and related health issues, substantial political and advocacy efforts on a global scale are essential [98]. And 4) health education and condom use: health education initiatives have focused on enhancing condom use, reducing the number of sexual partners, and promoting safer sex practices to reduce HPV transmission. Promoting condom use was found to be the most effective intervention strategy [99].

2. Importance of continued research and public health efforts to address HPV-related gynecological cancers

Continued research and public health efforts are of the utmost importance in addressing HPV-related gynecological cancers. HPV infection plays a significant role in increasing the risk of developing cervical, vulvar, vaginal, and anal cancers [100]. These cancers have significant morbidity and mortality rates, and prevention strategies, such as HPV vaccination and screening tests, have shown promise for reducing the burden of these diseases [101].

Research plays a crucial role in understanding the epidemiology, natural history, and pathogenesis of HPV-related gynecological cancers. It helps to identify high-risk populations, assess the effectiveness of prevention strategies, and develop new interventions. Research has indicated that the history of HPV-related gynecological cancer is strongly linked to anal cancer. This highlights the importance of comprehensive screening and prevention strategies [102].

Public health efforts are essential to implement and promote HPV vaccination programs and cervical cancer screening. These efforts involve raising awareness, improving access to vaccines and screening tests, and ensuring the equitable distribution of resources. Ongoing evaluation and monitoring of these programs are necessary to ensure their effectiveness and identify areas for improvement [103].

Notes

Conflict of interest

The other authors also have no conflicts of interest.

Ethical approval

None.

Patient consent

None.

Funding information

None.

References

1. Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One 20145;9:e88323.
2. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010;46:S20–6.
3. Khan A, Abonyi S, Neudorf C. Barriers and facilitators in uptake of human papillomavirus vaccine across English Canada: a review. Hum Vaccin Immunother 2023;19:2176640.
4. Carmichael JA, Maskens PD. Cervical dysplasia and human papillomavirus. Am J Obstet Gynecol 1989;160:916–8.
5. Mrklas KJ, MacDonald S, Shea-Budgell MA, Bedingfield N, Ganshorn H, Glaze S, et al. Barriers, supports, and effective interventions for uptake of human papilloma-virus- and other vaccines within global and Canadian Indigenous peoples: a systematic review protocol. Syst Rev 2018;7:40.
6. Deak P. What I tell every patient about the HPV vaccine [Internet]. Washington (DC): American College of Obstetrics and Gynecology; c2024. [cited 2025 Jan 10]. Available from: https://www.acog.org/womens-health/experts-and-stories/the-latest/what-i-tell-every-patient-about-the-hpv-vaccine.
7. Shapiro GK. HPV vaccination: an underused strategy for the prevention of cancer. Curr Oncol 2022;29:3780–92.
8. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV): web annex C: evidence-to-decision framework for dual-stain cytology to triage women after a positive test for human papillomavirus (HPV) [Internet]. Geneva: World Health Organization; c2024. [cited 2024 Aug 13]. Available from: http://dx.doi.org/10.2471/b09020.
9. Soheili M, Keyvani H, Soheili M, Nasseri S. Human papilloma virus: a review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers. Med J Islam Repub Iran 2021;35:65.
10. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8–15.
11. Centers for Disease Control and Prevention. Chapter 11: human papillomavirus [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; c2024. [cited 2024 Oct 21]. Available from: https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-11-human-papillomavirus.html.
12. Ardekani A, Taherifard E, Mollalo A, Hemadi E, Roshanshad A, Fereidooni R, et al. Human papillomavirus infection during pregnancy and childhood: a comprehensive review. Microorganisms 2022;10:1932.
13. Petca A, Borislavschi A, Zvanca ME, Petca RC, Sandru F, Dumitrascu MC. Non-sexual HPV transmission and role of vaccination for a better future (Review). Exp Ther Med 2020;20:186.
14. Dubel J, Dubel R, Ruszel K, Czekaj A, Namroży N. Vaccination against HPV (human papilloma virus) for women-why is it still recommended and not obligatory in Poland? J Educ Health Sport 2023;13:112–6.
15. Satanova AR, Kaidarova D, Kukubassov E, Bolatbekova R, Kaldybekov D, Bertleuov O. The global prevalence of human papillomavirus causing cervical cancer: a literature review. Oncol Radiol Kaz 2022;3:42–6.
16. López ED. Vaccination against human papillomavirus (HPV) in vulnerable populations - sexual minorities [Internet]. London: IntechOpen; c2022. [cited 2025 Jan 10]. Available from: https://www.intechopen.com/chapters/80380.
17. Kost BP, Hofmann J, Stoellnberger S, Bergauer F, Blankenstein T, Alba-Alejandre I, et al. Prevalence of human papillomavirus infection of the anal canal in women: a prospective analysis of high-risk populations. Oncol Lett 2017;13:2495–501.
18. Yu Y, Xu M, Sun J, Li R, Li M, Wang J, et al. Human papillomavirus infection and vaccination: awareness and knowledge of HPV and acceptability of HPV vaccine among mothers of teenage daughters in Weihai, Shandong, China. PLoS One 2016;11e0146741.
19. Ai M. Relationship between human papillomavirus infection and cervical cancer progression. Infection International 2015;4:21–5.
20. Madhivanan P, Bokulich N, Coudray M, Colbert B, Ruiz-Perez D, Krupp K, et al. Composition of the vaginal microbiome associated with high risk HPV infection and increased risk for cervical cancer. Cancer Epidemiol Biomarkers Prev 2020;29:696.
21. Nagandla K, Lin KH, Chitra E, Jamli MFBM. Role of microRNAs as biomarkers of cervical carcinogenesis: a systematic review. Obstet Gynecol Sci 2021;64:419–36.
22. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4:46–55.
23. Palefsky J. Biology of HPV in HIV infection. Adv Dent Res 2006;19:99–105.
24. Singh N, Hussain S, Sharma U, Suri V, Nijhawan R, Bharadwaj M, et al. The protective role of the -1306C>T functional polymorphism in matrix metalloproteinase-2 gene is associated with cervical cancer: implication of human papillomavirus infection. Tumour Biol 2016;37:5295–303.
25. Bowden SJ, Doulgeraki T, Bouras E, Markozannes G, Athanasiou A, Grout-Smith H, et al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies. BMC Med 2023;21:274.
26. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005;23:2388–94.
27. Barbosa MS, Vass WC, Lowy DR, Schiller JT. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol 1991;65:292–8.
28. Kovelman R, Bilter GK, Glezer E, Tsou AY, Barbosa MS. Enhanced transcriptional activation by E2 proteins from the oncogenic human papillomaviruses. J Virol 1996;70:7549–60.
29. Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol 2006;44:1310–7.
30. Kusanagi Y, Kojima A, Mikami Y, Kiyokawa T, Sudo T, Yamaguchi S, et al. Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Pathol 2010;177:2169–75.
31. Kong TW, Kim M, Kim YH, Kim YB, Kim J, Kim JW, et al. High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology. J Gynecol Oncol 2020;31e31.
32. Hoang HT, Ishizaki A, Nguyen CH, Tran VT, Matsushita K, Saikawa K, et al. Infection with high-risk HPV types among female sex workers in northern Vietnam. J Med Virol 2013;85:288–94.
33. Castle PE, Cremer M. Human papillomavirus testing in cervical cancer screening. Obstet Gynecol Clin North Am 2013;40:377–90.
34. Bai A, Xue P, Li Q, Jiang Y, Qiao Y. Diagnostic value of high-risk HPV other than type 16/18 in high-grade cervical neoplasia among cytology-negative women: a multicenter retrospective study. Cancer Med 2023;12:14794–805.
35. Musa J, Maiga M, Green SJ, Magaji FA, Maryam AJ, Okolo M, et al. Vaginal microbiome community state types and high-risk human papillomaviruses in cervical precancer and cancer in North-central Nigeria. BMC Cancer 2023;23:683.
36. Condic M, Neidhöfer C, Ralser DJ, Wetzig N, Thiele R, Sieber M, et al. Analysis of the cervical microbiome in women from the German national cervical cancer screening program. J Cancer Res Clin Oncol 2023;149:6489–500.
37. Rad A, Sørbye SW, Brenn T, Tiwari S, Løchen ML, Skjeldestad FE. 13-type HPV DNA test versus 5-type HPV mRNA test in triage of women aged 25-33 years with minor cytological abnormalities-6 years of followup. Int J Environ Res Public Health 2023;20:4119.
38. Sudhakaran S, Bhatla N, Mathur SR, Mahey R, Vashist S, Natarajan J, et al. Evaluation of cervical cancer screening during pregnancy in India: human papillomavirus testing can change the paradigm. Natl Med J India 2023;36:17–21.
39. Lawson O, Ameyan L, Tukur Z, Dunu S, Kerry M, Okuyemi OO, et al. Cervical cancer screening outcomes in public health facilities in three states in Nigeria. BMC Public Health 2023;23:1688.
40. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev Mol Diagn 2008;8:599–605.
41. Martinelli M, Giubbi C, Di Meo ML, Perdoni F, Musumeci R, Leone BE, et al. Accuracy of human papillomavirus (HPV) testing on urine and vaginal self-samples compared to clinician-collected cervical sample in women referred to colposcopy. Viruses 2023;15:1889.
42. Nakowong P, Chatchawal P, Chaibun T, Boonapatcharoen N, Promptmas C, Buajeeb W, et al. Detection of high-risk HPV 16 genotypes in cervical cancers using isothermal DNA amplification with electrochemical genosensor. Talanta 2024;269:125495.
43. Barroeta JE. The future role of cytology in cervical cancer screening in the era of HPV vaccination. Acta Cytologica 2023;67:111–8.
44. Acevedo-Fontanez AI, Suarez E, Torres-Cintron CR, Ortiz AP. Abstract LB-166: risk of anal cancer in women with human papillomavirus-related gynecological neoplasm: puerto rico 1987-2013. Cancer Res 2017;77:LB–166.
45. Yamazaki T. Two cases of human papillomavirus-related oropharyngeal cancer after the treatment of cervical cancer. Cureus 2020;12e8434. .
46. Riethmuller D, Jacquard AC, Lacau St Guily J, Aubin F, Carcopino X, Pradat P, et al. Potential impact of a non-avalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health 2015;15:453.
47. Zahnd WE, Rodriguez C, Jenkins WD. Rural-urban differences in human papillomavirus-associated cancer trends and rates. J Rural Health 2019;35:208–15.
48. Bernabe-Dones RD, Gonzalez-Pons M, Villar-Prados A, Lacourt-Ventura M, Rodríguez-Arroyo H, Fonseca-Williams S, et al. High prevalence of human papillomavirus in colorectal cancer in hispanics: a case-control study. Gastroenterol Res Pract 2016;2016:7896716.
49. Smith EM, Swarnavel S, Ritchie JM, Wang D, Haugen TH, Turek LP. Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J 2007;26:836–40.
50. Nielsen A, Kjaer SK, Munk C, Iftner T. Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis 2008;35:276–82.
51. Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol 2014;50:380–6.
52. Scheel A, Lin GC, McHugh JB, Komarck CM, Walline HM, Prince ME, et al. Human papillomavirus infection and biomarkers in sinonasal inverted papillomas: clinical significance and molecular mechanisms. Int Forum Allergy Rhinol 2015;5:701–7.
53. Teixeira MF, Sabidó M, Leturiondo AL, de Oliveira Ferreira C, Torres KL, Benzaken AS. High risk human papillomavirus prevalence and genotype distribution among women infected with HIV in Manaus, Amazonas. Virol J 2018;15:36.
54. Sehnal B, Podlešák T, Kmoníčková E, Nipčová M, Driák D, Sláma J, et al. Anogenital HPV infection as the potential risk factor for oropharyngeal carcinoma. Klin Onkol 2018;31:103–9.
55. Nang DW, Tukirinawe H, Okello M, Tayebwa B, Theophilus P, Sikakulya FK, et al. Prevalence of high-risk human papillomavirus infection and associated factors among women of reproductive age attending a rural teaching hospital in western Uganda. BMC Womens Health 2023;23:209.
56. Martínez-Gómez X, Curran A, Campins M, Alemany L, Rodrigo-Pendás JÁ, Borruel N, et al. Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016. Euro Surveill 2019;24:1700857.
57. Gerend MA, Stephens YP, Kazmer MM, Slate EH, Reyes E. Predictors of human papillomavirus vaccine completion among low-income Latina/o adolescents. J Adolesc Health 2019;64:753–62.
58. Leung SOA, Akinwunmi B, Elias KM, Feldman S. Educating healthcare providers to increase human papillomavirus (HPV) vaccination rates: a qualitative systematic review. Vaccine X 2019;3:100037.
59. Abi Jaoude J, Saad H, Farha L, Dagher H, Khair D, Kaafarani MA, et al. Barriers, attitudes and clinical approach of lebanese physicians towards HPV vaccination; a cross- sectional study. Asian Pac J Cancer Prev 2019;20:3181–7.
60. Whitworth HS, Gallagher KE, Howard N, Mounier-Jack S, Mbwanji G, Kreimer AR, et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: a systematic review of evidence from clinical trials. Vaccine 2020;38:1302–14.
61. Sonawane K, Zhu Y, Montealegre JR, Lairson DR, Bauer C, McGee LU, et al. Parental intent to initiate and complete the human papillomavirus vaccine series in the USA: a nationwide, cross-sectional survey. Lancet Public Health 2020;5:e484–92.
62. Lin C, Mullen J, Smith D, Kotarba M, Kaplan SJ, Tu P. Healthcare providers’ vaccine perceptions, hesitancy, and recommendation to patients: a systematic review. Vaccines (Basel) 2021;9:713.
63. Galvin AM, Garg A, Griner SB, Moore JD, Thompson EL. Health literacy correlates to HPV vaccination among US adults ages 27-45. J Cancer Educ 2023;38:349–56.
64. Patrick L, Bakeera-Kitaka S, Rujumba J, Malande OO. Encouraging improvement in HPV vaccination coverage among adolescent girls in Kampala, Uganda. PLoS One 2022;17e0269655.
65. McNamara M, Batur P, Walsh JME, Johnson KM. HPV update: vaccination, screening, and associated disease. J Gen Intern Med 2016;31:1360–6.
66. Arevalo M, Brownstein NC, Whiting J, Vadaparampil ST, Head KJ, Meade CD, et al. Factors related to human papillomavirus vaccine uptake and intentions among adults aged 18-26 and 27-45 years in the United States: a cross-sectional study. Cancer 2023;129:1237–52.
67. Konishi I. Precision medicine in gynecology and obstetrics. In : Ino K, ed. Prevention of cervical cancer: era of HPV testing and vaccination 1st edth ed. Singapore: Springer Singapore; 2017. p. 87–99.
68. Elfström KM, Herweijer E, Sundström K, Arnheim-Dahlström L. Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination: a review. Curr Opin Oncol 2014;26:120–9.
69. Snyman LC, Dreyer G, Botha MH, van der Merwe FH, Becker PJ. The vaccine and cervical cancer screen (VACCS) project: linking cervical cancer screening to HPV vaccination in the south-west district of Tshwane, Gauteng, South Africa. S Afr Med J 2015;105:115–20.
70. del Carmen MG. Cervical cancer: will interventions to HPV vaccination reduce disparities? Curr Women’s Health Rev 2018;14:235–41.
71. Silver MI, Kobrin S. Exacerbating disparities?: cervical cancer screening and HPV vaccination. Prev Med 2020;130:105902.
72. Ong SK, Abe SK, Thilagaratnam S, Haruyama R, Pathak R, Jayasekara H, et al. Towards elimination of cervical cancer - human papillomavirus (HPV) vaccination and cervical cancer screening in Asian National Cancer Centers Alliance (ANCCA) member countries. Lancet Reg Health West Pac 2023;39:100860. .
73. Murillo R, Ordóñez-Reyes C. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs. Int J Gynecol Cancer 2019;29:1317–26.
74. Diaz M, de Sanjose S, Ortendahl J, O’Shea M, Goldie SJ, Bosch FX, et al. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer 2010;46:2973–85.
75. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007;111:145–53.
76. Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24 Suppl 3:1–10.
77. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–9.
78. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757–65.
79. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009;2:868–78.
80. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81–6.
81. Dalal NH, Chino F, Williamson H, Beasley GM, Salama AKS, Palta M. Mind the gap: gendered publication trends in oncology. Cancer 2020;126:2859–65.
82. Abdou Y, Goudarzi A, Yu JX, Upadhaya S, Vincent B, Carey LA. Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors. NPJ Breast Cancer 2022;8:121.
83. Levin G, Kogan L, Matan L, Brandt B, Meyer R, Perri T. Positive results bias in randomized controlled trials in gynecologic oncology. Arch Gynecol Obstet 2024;309:1681–3.
84. Thomas C. HPV vaccines: bring me your daughters! S Afr Med J 2008;98:259–61.
85. Khorasanizadeh F, Hassanloo J, Khaksar N, Mohammad Taheri S, Marzaban M, Rashidi BH, et al. Epidemiology of cervical cancer and human papilloma virus infection among Iranian women - analyses of national data and systematic review of the literature. Gynecol Oncol 2013;128:277–81.
86. Cole K, Al-Kadhimi Z, Talmadge JE. Highlights into historical and current immune interventions for cancer. Int Immunopharmacol 2023;117:109882.
87. Zhang L, Zhou F, Zhao KN. Molecular approaches target to immunotherapy for HPV-associated cancers. Curr Cancer Drug Targets 2017;17:512–21.
88. Zoa Assoumou S, Ndjoyi Mbiguino A, Mabika Mabika B, Nguizi Ogoula S, El Mzibri M, Khattabi A, et al. Human papillomavirus genotypes distribution among Gabonese women with normal cytology and cervical abnormalities. Infect Agent Cancer 2016;11:2.
89. Lima SF Júnior, Tavares MM, Macedo JL, Oliveira RS, Heráclio SA, Maia MM, et al. Influence of IL-6, IL-8, and TGF-β1 gene polymorphisms on the risk of human papillomavirus-infection in women from Pernambuco, Brazil. Mem Inst Oswaldo Cruz 2016;111:663–9.
90. Arora S, Ramachandra SS, Squier C. Knowledge about human papillomavirus (HPV) related oral cancers among oral health professionals in university setting-a cross sectional study. J Oral Biol Craniofac Res 2018;8:35–9.
91. Rubey KM, Brenner JS. Nanomedicine to fight infectious disease. Adv Drug Deliv Rev 2021;179:113996.
92. Mukherjee AG, Wanjari UR, Gopalakrishnan AV, Kannampuzha S, Murali R, Namachivayam A, et al. Exploring the molecular pathogenesis, pathogen association, and therapeutic strategies against HPV infection. Pathogens 2022;12:25.
93. Lin YY, Alphs H, Hung CF, Roden RB, Wu TC. Vaccines against human papillomavirus. Front Biosci 2007;12:246–64.
94. Gohar A, Ali AA, Elkhatib WF, El-Sayyad GS, Elfadil D, Noreddin AM. Combination therapy between prophylactic and therapeutic human papillomavirus (HPV) vaccines with special emphasis on implementation of nanotechnology. Microb Pathog 2022;171:105747.
95. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013;31 Suppl 5:F1–31.
96. Ino K. Prevention of cervical cancer: era of HPV testing and vaccination. In: Ino K, editor. Precision medicine in gynecology and obstetrics. Singapore: Springer; 2017. p.87-99.
97. Eun TJ, Perkins RB. Screening for cervical cancer. Med Clin North Am 2020;104:1063–78.
98. Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane MA. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine 2012;30Suppl 5:F1–11.
99. Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol 2007;107:S19–23.
100. Jiménez W, Paszat L, Kupets R, Wilton A, Tinmouth J. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol 2009;114:395–8.
101. Phoolcharoen N, Baker ES, Salcedo MP. Cervical cancer screening 2nd edth ed. Cham: Springer International Publishing; 2021.
102. Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination-review of current perspectives. J Oncol 2019;2019:3257939.
103. Saraiya M, Steben M, Watson M, Markowitz L. Evolution of cervical cancer screening and prevention in United States and Canada: implications for public health practitioners and clinicians. Prev Med 2013;57:426–33.

Article information Continued